Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Pollak, Eliezer Rachmilewitz, Anat Blumenfeld, M. Idelson, Ada Goldfarb (2000)
Bone mineral metabolism in adults with beta-thalassaemia major and intermedia.British journal of haematology, 111 3
P. Szulc, L. Hofbauer, A. Heufelder, S. Roth, P. Delmas (2001)
Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status.The Journal of clinical endocrinology and metabolism, 86 7
SK Lee, JA Lorenzo (1999)
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formationEndocrinology, 140
Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with
H. Valleala, J. Mandelin, L. Laasonen, M. Koivula, J. Risteli, Y. Konttinen (2003)
Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.European journal of endocrinology, 148 5
N. Morabito, A. Gaudio, A. Lasco, M. Atteritano, Maria Pizzoleo, M. Cincotta, M. Rosa, Roberta Guarino, A. Meo, N. Frisina (2004)
Osteoprotegerin and RANKL in the Pathogenesis of Thalassemia‐Induced Osteoporosis: New Pieces of the PuzzleJournal of Bone and Mineral Research, 19
M. Zaidi, H. Blair, B. Moonga, E. Abe, C. Huang (2003)
Osteoclastogenesis, Bone Resorption, and Osteoclast‐Based TherapeuticsJournal of Bone and Mineral Research, 18
W. Browner, W. Browner, L. Lui, S. Cummings (2001)
Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.The Journal of clinical endocrinology and metabolism, 86 2
J. Body, A. Lortholary, G. Romieu, A. Vigneron, J. Ford (1999)
A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 14
P. Kostenuik, Victoria Shalhoub (2001)
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.Current pharmaceutical design, 7 8
L. Low, M. Postel‐Vinay, E. Kwan, P. Cheung (1998)
Serum growth hormone (GH) binding protein, IGF‐I and IGFBP‐3 in patients with β‐thalassaemia major and the effect of GH treatmentClinical Endocrinology, 48
PJ Giardina, R Schneider, M Lesser, B Simmons, A Rodriguez, J Gertner (1995)
Endocrine disorders in thalassaemia
M. Murphy, Stuart Weiss, M. McClung, Thomas Schnitzer, K. Cerchio, J. Connor, D. Krupa, Barry Gertz (2001)
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.The Journal of clinical endocrinology and metabolism, 86 3
E. Voskaridou, M. Kyrtsonis, E. Terpos, Maroussa Skordili, I. Theodoropoulos, Angeliki Bergele, E. Diamanti, A. Kalovidouris, A. Loutradi, D. Loukopoulos (2001)
Bone resorption is increased in young adults with thalassaemia majorBritish Journal of Haematology, 112
R. Pollak, E. Rachmilewitz, A. Blumenfeld, M. Idelson, A. Goldfarb (2000)
Bone mineral metabolism in adults with β‐thalassaemia major and intermediaBritish Journal of Haematology, 111
M. Murphy, M. Bach, D. Plotkin, James Bolognese, J. Ng, D. Krupa, K. Cerchio, Barry Gertz (1999)
Oral Administration of the Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly AdultsJournal of Bone and Mineral Research, 14
C. Ohlsson, C. Ohlsson, B. Bengtsson, O. Isaksson, T. Andreassen, M. Slootweg (1998)
Growth hormone and bone.Endocrine reviews, 19 1
Dalma Hegedűs, V. Ferencz, P. Lakatos, S. Mészáros, P. Lakatos, C. Horváth, Ferenc Szalay (2002)
Decreased Bone Density, Elevated Serum Osteoprotegerin, and β‐Cross‐Laps in Wilson DiseaseJournal of Bone and Mineral Research, 17
P. Mahachoklertwattana, A. Chuansumrit, R. Sirisriro, L. Choubtum, A. Sriphrapradang, R. Rajatanavin (2003)
Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease.Clinical endocrinology, 58 3
A. Lasco, N. Morabito, A. Gaudio, A. Crisafulli, A. Meo, G. Denuzzo, N. Frisina (2002)
Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.Journal of endocrinological investigation, 25 4
A. Herington, G. Werther, R. Matthews, H. Burger (1981)
Studies on the possible mechanism for deficiency of nonsuppressible insulin-like activity in thalassemia major.The Journal of clinical endocrinology and metabolism, 52 3
(2000)
The relationship between circulating osteoprotegerin and estrogen in postmenopausal women
P. Major, A. Lortholary, J. Hon, E. Abdi, G. Mills, H. Menssen, F. Yunus, R. Bell, J. Body, E. Quebe‐Fehling, J. Seaman (2001)
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
J. Kapitola, J. Žák, Z. Lacinová, V. Justová (2000)
Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat.Physiological research, 49 Suppl 1
E. Voskaridou, E. Terpos, G. Spina, J. Palermos, A. Rahemtulla, Aphroditi Loutradi, D. Loukopoulos (2003)
Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemiaBritish Journal of Haematology, 123
LC Hofbauer, AE Heufelder (2000)
The role of osteoprotegerin and receptor activator of NF-κB ligand in the pathogenesis and treatment of metabolic bone diseasesJ Clin Endocrinol Metab, 85
V. Viereck, G. Emons, Vanessa Lauck, K. Frosch, S. Blaschke, C. Gründker, L. Hofbauer (2002)
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.Biochemical and biophysical research communications, 291 3
AT Solima, MM ElZalabany, Y. Mazloum, Sma Bedair, Ragab, A. Rogol, B. Ansari (1999)
Spontaneous and provoked growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) concentration in patients with beta thalassaemia and delayed growth.Journal of tropical pediatrics, 45 6
Diana Rucker, S. Ezzat, A. Diamandi, J. Khosravi, D. Hanley (2004)
IGF‐I and testosterone levels as predictors of bone mineral density in healthy, community‐dwelling menClinical Endocrinology, 60
J. Cornish, A. Grey, K. Callon, D. Naot, B. Hill, Cindy Lin, L. Balchin, I. Reid (2004)
Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1.Biochemical and biophysical research communications, 318 1
A. Soliman, N. Banna, B. Ansari (1998)
GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia.European journal of endocrinology, 138 4
L. Cavallo, R. Gurrado, F. Gallo, C. Zecchino, D. Mattia, L. Tató (1997)
Growth deficiency in polytransfused β‐thalassaemia patients is not growth hormone dependentClinical Endocrinology, 46
L. Hofbauer, M. Schoppet (2001)
Serum measurement of osteoprotegerin--clinical relevance and potential applications.European journal of endocrinology, 145 6
L. Hofbauer, A. Heufelder (2000)
The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1The Journal of Clinical Endocrinology and Metabolism, 85
L. Hofbauer, A. Heufelder (2001)
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biologyJournal of Molecular Medicine, 79
W. Simonet, D. Lacey, C. Dunstan, M. Kelley, Ming-Shi Chang, R. Lüthy, Hung Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H. Tan, Geraldine Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W. Boyle (1997)
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 89
D. Faulkner, C. Young, D. Hutchins, Jill McCollam (1998)
Patient Noncompliance with Hormone Replacement Therapy: A Nationwide Estimate Using a Large Prescription Claims DatabaseMenopause, 5
(2000)
Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH(1–34)
J. Onyia, J. Onyia, R. Miles, Xianlin Yang, D. Halladay, J. Hale, A. Glasebrook, D. McClure, G. Seno, L. Churgay, S. Chandrasekhar, T. Martin, T. Martin (2000)
In Vivo Demonstration that Human Parathyroid Hormone 1–38 Inhibits the Expression of Osteoprotegerin in Bone with the Kinetics of an Immediate Early GeneJournal of Bone and Mineral Research, 15
R. Erdtsieck, H. Pols, N. Valk, B. Ouwerkerk, S. Lamberts, Paul Mulder, Jan Birkenhäger (1995)
Treatment of post‐menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trialClinical Endocrinology, 43
Y. Kim, Gwan‐Shik Kim, J. Baek (2002)
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expressionExperimental & Molecular Medicine, 34
B. Wonke (1998)
Bone disease in beta-thalassaemia major.British journal of haematology, 103 4
L. Álvarez, P. Peris, N. Guañabens, S. Vidal, Inmaculada Ros, F. Pons, X. Filella, A. Monegal, J. Muñoz‐Gómez, A. Ballesta (2003)
Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.Arthritis and rheumatism, 48 3
M. Horowitz, Yougen Xi, Kimberly Wilson, M. Kacena (2001)
Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.Cytokine & growth factor reviews, 12 1
A. Lasco, N. Morabito, A. Gaudio, A. Crisafulli, A. Meo, G. Denuzzo, Nicola Frisina (2002)
Osteoporosis and β-thalassemia major: Role of the IGF-I/IGFBP-III axisJournal of Endocrinological Investigation, 25
K. Abbott, Victor Bernet, L. Agodoa, C. Yuan (2003)
Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome after renal transplantation in the United StatesBMC Endocrine Disorders, 3
D. Chrysis, T. Alexandrides, Era Koromantzou, N. Georgopoulos, P. Vassilakos, W. Kiess, Jürgen Kratsch, N. Beratis, B. Spiliotis (2001)
Novel application of IGF‐I and IGFBP‐3 generation tests in the diagnosis of growth hormone axis disturbances in children with β‐thalassaemiaClinical Endocrinology, 54
A. Shamshirsaz, M. Bekheirnia, M. Kamgar, N. Pourzahedgilani, N. Bouzari, M. Habibzadeh, R. Hashemi, A. Shamshirsaz, S. Aghakhani, Hooman Homayoun, B. Larijani (2003)
Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in TehranBMC Endocrine Disorders, 3
C. Tirpitz, Jochen Klaus, M. Steinkamp, L. Hofbauer, Wolfgang Kratzer, Richard Mason, Bernhard Boehm, Gail Adler, M. Reinshagen (2003)
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronateAlimentary Pharmacology & Therapeutics, 17
E. Seeman, C. Tsalamandris, S. Bass, G. Pearce (1996)
Present and future of osteoporosis therapy.Bone, 17 2 Suppl
L. Ruggiero, V. Sanctis (1998)
Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients.Journal of pediatric endocrinology & metabolism : JPEM, 11 Suppl 3
A. Soliman, N. Banna, M. Fattah, M. Elzalabani, B. Ansari (1998)
Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data.Metabolism: clinical and experimental, 47 5
K. Yano, E. Tsuda, N. Washida, Fumie Kobayashi, M. Goto, A. Harada, K. Ikeda, K. Higashio, Y. Yamada (1999)
Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with OsteoporosisJournal of Bone and Mineral Research, 14
P. Pennisi, G. Pizzarelli, M. Spina, S. Riccobene, C. Fiore (2003)
Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosisJournal of Bone and Mineral Metabolism, 21
B. Wonke (1998)
BONE DISEASE IN β‐THALASSAEMIA MAJORBritish Journal of Haematology, 103
D. Lacey, E. Timms, H. Tan, M. Kelley, C. Dunstan, Tim Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, Charles Capparelli, A. Eli, Y. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, Jane Guo, J. Delaney, W. Boyle (1998)
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 93
N. Fazzalari, J. Kuliwaba, G. Atkins, M. Forwood, D. Findlay (2001)
The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in OsteoarthritisJournal of Bone and Mineral Research, 16
N. Morabito, A. Lasco, A. Gaudio, A. Crisafulli, C. Pietro, A. Meo, N. Frisina (2002)
Bisphosphonates in the Treatment of Thalassemia-Induced OsteoporosisOsteoporosis International, 13
P. Geusens, S. Boonen (2002)
Osteoporosis and the Growth Hormone-Insulin-Like Growth Factor AxisHormone Research in Paediatrics, 58
Professor Kanis (1994)
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 4
P. Mahachoklertwattana, V. Sirikulchayanonta, A. Chuansumrit, Patcharee Karnsombat, L. Choubtum, A. Sriphrapradang, S. Domrongkitchaiporn, R. Sirisriro, R. Rajatanavin (2003)
Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia.The Journal of clinical endocrinology and metabolism, 88 8
I. Reid, Jacques Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J. Devogelaer, J. Kaufman, P. Jaeger, J. Body, M. Brandi, J. Broell, R. Micco, A. Genazzani, D. Felsenberg, J. Happ, M. Hooper, J. Ittner, G. Leb, H. Mallmin, T. Murray, S. Ortolani, A. Rubinacci, M. Saaf, G. Samsioe, L. Verbruggen, P. Meunier (2002)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.The New England journal of medicine, 346 9
P. Giardina, R. Schneider, M. Lesser, B. Simmons, A. Rodríguez, J. Gertner, M. New, M. Hilgartner (1995)
Abnormal Bone Metabolism in Thalassemia
E. Voskaridou, E. Terpos (2004)
New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemiaBritish Journal of Haematology, 127
Jensen Ce, S. Tuck, A. Je, S. Koneru, R. Morris, A. Yardumian, E. Prescott, A. Hoffbrand, B. Wonke (1998)
High prevalence of low bone mass in thalassaemia majorBritish Journal of Haematology, 103
A. Lasco, N. Morabito, A. Gaudio, M. Buemi, M. Wasniewska, N. Frisina (2001)
Effects of Hormonal Replacement Therapy on Bone Metabolism in Young Adults with Beta-thalassemia MajorOsteoporosis International, 12
Osteoporosis has emerged as an important cause of morbidity in patients with thalassemia major. Studies regarding the efficacy of bisphosphonates in thalassemia-induced osteoporosis have yielded conflicting results. We performed this prospective study to evaluate the efficacy of zoledronic acid in osteoporotic patients with thalassemia major. Patients, 29, were given 1 mg zoledronic acid intravenously every 3 months for a total of four doses. Twenty age- and sex-matched healthy blood donors served as controls. Before each infusion and 3 months after the last infusion, we determined serum levels of osteoprotegerin (OPG), N-terminal cross-linking telopeptide of type I collagen (NTX), osteocalcin (OC) and insulin-like growth factor 1 (IGF-1). Bone mineral density (BMD) of the lumbar spine was measured at baseline and after the treatment’s completion. At baseline, OPG did not differ significantly between patients and controls ( p =0.2), NTX were higher in patients although not significantly ( p =0.139), whereas, OC levels were significantly higher and IGF-1 levels significantly lower in patients than in controls ( p <0.001 and p <0.006, respectively). Zoledronic acid administration resulted in a significant decrease in NTX, OC and IGF-1 ( p <0.05, p <0.001 and p <0.05, respectively) and in a significant increase in OPG and BMD ( p <0.05 for both comparisons). The change in NTX, osteocalcin and IGF-1 became significant as early as 3 months after the first administration of zoledronic acid, while the change in OPG reached significance only after three infusions. Our study supports the effectiveness of bisphosphonates in the treatment of thalassemia-induced osteoporosis.
Annals of Hematology – Springer Journals
Published: Jan 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.